secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRA LIFESCIENCES HOLDINGS CORP (IART)
CIK:        0000917520
Form:       8-K
Filed at:   2024-11-04T23:59:59+00:00
Accession:  0000917520-24-000106
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Integra Q3 revenue down 0.4%, GAAP EPS loss; lowers FY2024 guidance; appoints new CEO
--------------------------------------------------------------------------------

- Revenue $380.8M, down 0.4% reported and 8.6% organic; GAAP EPS $(0.14) vs $0.24, adjusted EPS $0.41 vs $0.76.
- Neurosurgery organic sales -16% on shipping holds; Instruments +8.7%; Tissue Tech -3.7% organic, ex-Boston -9.4%.
- FY2024 revenue guidance lowered to $1.609-1.619B (organic -1.7% to -1.0%); adjusted EPS guided $2.41-$2.49.
- Mojdeh Poul named next president and CEO, effective Jan 6, 2025, succeeding retiring Jan De Witte.
- Shipping holds releasing in line with expectations; Integra Skin production on pace for Q4 historical run rates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/917520/000091752024000106/0000917520-24-000106-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/917520/000091752024000106/iart-20241104.htm
  HTML page:      https://secwatch.observer/filing/0000917520-24-000106

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer